Clinical Chemistry ELISA
Troponin l (Human Cardiac-Specific)
Enzyme Immunoassay Test Kit
Enzyme Immunoassay for the Quantitative
Determination of Cardiac-Specific Troponin-I
in Human Serum
for in vitro diagnostic use
Product Description
Troponin is the inhibitory or contractile regulating protein
complex of striated muscle. It is located periodically along
the thin filament of the muscle and consists of three distinct
proteins: troponin I, troponin C, and troponin T.1-5 Likewise,
the troponin I subunit exists in three separate isoforms;
two in fast-twitch and slow-twitch skeletal muscle fibers,
and one in cardiac muscle.6-8 The cardiac isoform (cTnI) is
about 40% dissimilar, has a molecular weight of 22,500 daltons,
and has 31 additional amino acid residues that are not present
on the skeletal isoforms. Antibodies made against this cardiac
isoform are immunologically different from antibodies made
against the other two skeletal isoforms, and the unique isoform
and tissue specificity of cardiac troponin I is the basis
for its use as an aid in the diagnosis of acute myocardial
infarction (AMI).
Cardiac troponin I (cTnI) has been useful in the differential
diagnosis of patients presenting to Emergency Departments
(ED) with chest pain. Myocardial infarction is diagnosed when
blood levels of sensitive and specific biomarkers, such as
cardiac troponin, the MB isoenzyme of creatine kinase (CK-MB),
and myoglobin, are increased in a clinical setting of acute
ischemia.
The most recently described and preferred biomarker for myocardial
damage is cardiac troponin (I or T). The cardiac troponins
exhibit myocardial tissue specificity and high sensitivity.
Likewise, cardiac TnI and CK-MB have similar release patterns
(4-6 hours after the onset of pain), but the level of cTnI
remains elevated for a much longer period of time (6-10 days),
thus providing for a longer window of detection of cardiac
injury.
Normal levels of cTn I in the blood are very low. After the
onset of an AMI, cTnI levels increase substantially and are
measurable in serum within 4 to 6 hours, with peak concentrations
reached in approximately 12 to 24 hours after infarction.
The fact that cTnI remains elevated in serum for a much longer
period of time, added to its enhanced diagnostic sensitivity
and cardiac specificity, allows for the detection of AMI much
earlier after the onset of ischemia (4 hours), as well as
the diagnosis of peri-operative infarction in situations where
a high serum level of skeletal muscle proteins are expected.
Additionally, recent data have identified a measurable relationship
between cardiac troponin levels and long-term outcome after
an episode of chest discomfort. The studies suggest that the
use of the cTnI demonstrates high predictive value in delineating
the high risk group of unstable angina patients and that these
tests may be particularly useful in evaluating patient condition
prior to discharge from the ED.
The cTnI Enzyme Immunoassay provides a rapid, sensitive, and
reliable assay for the quantitative measurement of cardiac-specific
troponin I. The antibodies developed for the test will determine
a minimal concentration of 1.0ng/ml, and there is no cross-reactivity
with human cardiac troponin T or skeletal troponin T or I.
Principle
The cTnI ELISA test is based on the principle of a solid phase
enzyme-linked immunosorbent assay. The assay system utilizes
four unique monoclonal antibodies directed against distinct
antigenic determinants on the molecule.
Three mouse monoclonal anti-troponin I antibodies are used
for solid phase immobilization (on the microtiter wells).
The fourth antibody is in the antibody-enzyme (horseradish
peroxidase) conjugate solution. The test sample is allowed
to react simultaneously with the four antibodies, resulting
in the troponin I molecules being sandwiched between the solid
phase and enzyme-linked antibodies.
After a 90-minute incubation at room temperature, the wells
are washed with water to remove unboundlabeled antibodies.
A solution of tetramethylbenzidine (TMB) Reagent is added
and incubated for 20 minutes, resulting in the development
of a blue color. The color development is stopped with the
addition of 1N hydrochloric acid (HCl) changing the color
to yellow.
The concentration of troponin I is directly proportional to
the color intensity of the test sample. Absorbance is measured
spectrophotometrically at 450nm.
Downloads: (Must be logged in)
Instruction PDF
|
 |
 |
|